Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC to consider Beconase switch, pediatric analgesic dosing at September meeting.

This article was originally published in The Tan Sheet

Executive Summary

BECONASE Rx-TO-OTC SWITCH REVIEW BY FDA's NDAC, PULMONARY-ALLERGY advisory committees is scheduled for Sept. 19. FDA's Nonprescription Drugs Advisory Committee, meeting jointly with the agency's Pulmonary-Allergy Drugs Advisory Committee, will consider NDA 20-840 for beclomethasone dipropionate nasal spray .042%. The switch NDA was filed by Glaxo Wellcome in December 1996 for the OTC treatment and prevention of seasonal allergic rhinitis symptoms in individuals over the age of 12. Glaxo will present studies in support of the switch of the product; however, if approved for OTC sale, Beconase will be marketed by Warner-Lambert under the companies' Rx-to-OTC switch joint venture.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel